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Abstract
Background/Aims—Drug-induced and indeterminate Acute Liver Failure (ALF) might be due 
to an autoimmune-like hepatitis that is responsive to corticosteroid therapy. The aim of this study 
was to evaluate whether corticosteroids improve survival in fulminant autoimmune hepatitis, drug-
induced or indeterminate ALF, and whether this benefit varies according to the severity of illness.
Methods—We conducted a retrospective analysis of autoimmune, indeterminate and drug-
induced ALF patients in the Acute Liver Failure Study Group from 1998-2007. The primary 
endpoints were overall and spontaneous survival (SS, survival without transplant).
Results—361 ALF patients were studied, 66 with autoimmune (25 steroids, 41 no steroids), 164 
with indeterminate (21 steroids, 143 no steroids), and 131 with drug-induced (16 steroids, 115 no 
steroids) ALF. Steroid use was not associated with improved overall survival (61% vs. 66%, 
p=0.41), nor with improved survival in any diagnosis category. Steroid use was associated with 
diminished survival in certain subgroups of patients, including those with the highest quartile of 
MELD (MELD > 40, survival 30% vs. 57%, p=0.03). In multivariable analysis controlling for 
steroid use and diagnosis, age (OR 1.37 per decade), coma grade (OR 2.02 grade 2, 2.65 grade 3, 
5.29 grade 4), MELD (OR 1.07) and pH<7.4 (OR 3.09) were significantly associated with 
mortality. Though steroid use was associated with a marginal benefit in SS overall (35% v. 23%, 
p=0.047), this benefit did not persistent in multivariable analysis; mechanical ventilation (OR 
0.24), MELD (OR 0.93), and ALT (1.02) were the only significant predictors of SS.
Conclusions—Corticosteroids did not improve overall survival or SS in drug-induced, 
indeterminate or autoimmune ALF and were associated with lower survival in patients with the 
highest MELD scores.
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Introduction
Acute liver failure (ALF) is a heterogeneous syndrome resulting in rapid deterioration of 
liver function with subsequent coagulopathy and encephalopathy in a previously healthy 
individual.1 Drug-induced (DI)-ALF is the most common etiology, the majority of which is 
due to the intrinsic hepatotoxin, acetaminophen,2 and the remainder due to idiosyncratic 
drug reactions, presumably immune-mediated liver injury due to the metabolic generation of 
a neo-antigen3. Approximately 4% of ALF cases are believed to be secondary to 
autoimmune acute liver failure (AI-ALF), although diagnostic criteria have not been well 
developed, and are primarily based upon criteria for patients with classical autoimmune 
hepatitis (AIH). The etiology of another 17% of ALF cases remains indeterminate after 
extensive evaluation. Recently, we have suggested that many patients with ALF of 
indeterminate etiology have AI-ALF, and have proposed histological features suggestive of 
an autoimmune pathogenesis.4
The prognosis of patients with non-acetaminophen-induced ALF remains very poor, with 
transplant-free or spontaneous survival (SS) rates of only 44%. Patients with idiosyncratic 
drug-induced, indeterminate, and AI-ALF have a particularly dismal SS rate of < 25%.2 
There are no etiology-specific treatments that have improved the prognosis of non-
acetaminophen ALF, and the trend toward increased SS in the last 30 years can be primarily 
attributed to improved critical care management.
The administration of glucocorticoids in patients with potentially immune-mediated ALF 
remains controversial after early studies suggested no benefit or even an adverse effect.5-7 
AI-ALF may theoretically respond to corticosteroids based upon their efficacy in patients 
who present with classical AIH and a few case reports of AI-ALF, although the largest series 
published to date concluded that corticosteroids might be harmful and may increase the risk 
of infection around the time of liver transplantation. 1,8,9 The use of corticosteroids has also 
been proposed as a potential treatment for idiosyncratic DI-ALF based upon a presumed 
immune-mediated pathogenesis6 and the fact that the innate immune system plays a key role 
in the development of ALF in humans and in animal models.10-12 In specific idiosyncratic 
drug reactions from HMG-CoA reductase inhibitors--“statins”, antibiotics, and non-steroidal 
anti-inflammatory drugs, glucocorticoid administration has ameliorated the liver injury. 8-13 
While it remains unclear whether these cases of DI-ALF induce bona fide AI-ALF or only 
mimic it, the frequent appearance of autoantibodies supports the former possibility. Based 
upon our previous observations that patients with indeterminate ALF have histological 
features of autoimmunity on liver biopsy, we also postulated that corticosteroids might also 
benefit this sub-population. The administration of corticosteroids may therefore represent an 
opportunity to reverse severe immune-mediated injury and obviate the need for liver 
transplantation.
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Consequently, the aim of the present study was to evaluate the efficacy of corticosteroids in 
improving overall survival and SS in 3 groups of ALF with a potentially autoimmune-
mediated pathogenesis: those with AI-ALF, indeterminate ALF, and DI-ALF. Considering 
the clinical heterogeneity of patients with the ALF syndrome, subgroup analyses were 
undertaken to determine whether the possible benefit of corticosteroids were associated with 
the severity of the clinical syndrome at time of presentation.
Materials and Methods
Patients and Study Design
We conducted a retrospective analysis of all patients enrolled in the Acute Liver Failure 
Study Group (ALFSG) Registry between 1998-2007 who were deemed to have either AI-
ALF, indeterminate ALF, or DI-ALF by the site Principal Investigator (PI). The ALFSG 
study cohort and its outcomes have been previously described. 16 A total of 361 consecutive 
patients were enrolled with ALF. Inclusion criteria included coagulopathy (international 
normalized ratio of prothrombin time [INR] ≥1.5) and any degree of hepatic encephalopathy. 
After informed consent was obtained from next of kin, detailed prospective clinical and 
laboratory data were collected in an anonymous fashion on admission to the study and for 7 
consecutive days until Day 21, or the time of death or liver transplantation. The protocol was 
IRB approved at all study sites as a prospective cohort and at UT Southwestern as the data-
coordinating center. The etiologies of ALF included indeterminate ALF (N = 164), DI-ALF 
(N = 131), and AI-ALF (N = 66). Each center determined whether a patient met criteria for 
AIH except where reclassified by histology (see below).
Primary end points were overall survival and spontaneous survival (SS), defined as survival 
without transplantation or death, by 21 days. The criteria for transplantation varied by 
center, however listing criteria are standardized. To be listed as Status 1 they had to meet 
UNOS criteria for ALF, which are similar to study entry criteria, including presence in the 
ICU, encephalopathy and a INR > 1.5. If a patient was not listed as Status 1, they were listed 
at their native MELD score.
The primary predictor was corticosteroid use, defined as any dose of prednisone PO or 
methylprednisolone IV. In half of the cases, treatment had been begun prior to onset of ALF 
while in the other half of cases the use of prednisone and related compounds began after the 
diagnosis of ALF had been made. The AI-ALF group was used as the control group for the 
corticosteroid benefit analyses. Sub-group analyses were performed using quartiles of AST, 
ALT, MELD and grade of hepatic encephalopathy as measures of the degree of hepatic 
inflammation and severity of illness. Infection was thought to be present when a positive 
culture from blood, urine, tracheal aspirates, vascular catheters, wounds or ascites was 
reported during study day 1-7. These data were initially analyzed based on the etiology of 
ALF. A diagnosis of AIH was made by histology (when available) and ANA and anti- 
smooth muscle antibody, as determined by the principal investigator at each center. In 
addition, for AI-ALF and indeterminate ALF patients, liver histopathology was reviewed 
specifically to identify features of autoimmunity. The effects of corticosteroids were then 
analyzed in a sensitivity analysis after group reassignment to AIH or indeterminate etiology 
according to the overall impression of a single liver pathologist, as previously described.4 
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The reassignment to AIH was based upon 4 features of autoimmunity: distinctive patterns of 
massive hepatic necrosis, presence of lymphoid follicles, plasma cell-enriched inflammatory 
infiltrate and central perivenulitis. Eight patients initially considered to have AI-ALF by the 
site PI were reclassified as indeterminate based upon absent features of autoimmunity, 2 of 
whom received corticosteroids. Twenty-six patients initially considered to have 
indeterminate ALF were found to have autoimmune features on histology and were 
reclassified as AI-ALF, 4 of whom received corticosteroids. Therefore, after reclassification 
according to histology, 84 patients were deemed to have AI-ALF (27 of whom received 
corticosteroids) and 146 were deemed to have indeterminate ALF (19 of whom received 
corticosteroids). The number of patients who received steroids and had a reclassified 
diagnosis was very small (2 patients reclassified from AI-ALF to indeterminate and 4 
patients reclassified from indeterminate to AI-ALF). Given the small N no statistically 
significant differences were noted when overall survival or spontaneous survival was 
calculated with the original diagnosis versus the reclassified diagnosis. Further subgroup 
analyses were not done given the small N. As no differences were noted when the original 
diagnosis was used versus the reclassified diagnosis in sensitivity analyses, all analyses 
reported utilize the original diagnosis (66 with autoimmune [25 steroids, 41 no steroids], 164 
with indeterminate [21 steroids, 143 no steroids], and 131 with drug-induced [16 steroids, 
115 no steroids] ALF.
Corticosteroid Administration
The decision whether to administer corticosteroids was entirely at the discretion of the site 
PI, and was based upon an overall impression of an immune pathogenesis; however, the 
specific criteria used by the site PI to administer corticosteroids were not available. The 
timing, route of administration, and dosing of corticosteroids was also according to the site 
PI, and were not uniform.
Statistical analysis
All data were analyzed for normality and were reported as mean [SD] or median [range], as 
appropriate. The impact of steroid use on the primary endpoints of overall mortality and SS 
were analyzed using a chi-square analysis. Because of the early time frame for death in ALF, 
time to event analyses were felt to be inappropriate as an increase in survival time in a 
twenty-one day period would not be clinically meaningful. Thus, sub-analyses were 
performed using quartiles of AST, ALT, MELD and grade of hepatic encephalopathy as 
measures of severity of illness (Quartile values listed in Supplemental Table 1). A sensitivity 
analyses were performed after reclassifying the etiology of ALF based on histology.
Additionally, univariate and multivariable logistic regression analyses were performed to 
evaluate predictors of overall mortality and SS. All predictors with p<0.2 in univariate 
analysis were evaluated in the multivariable model, and then sequentially removed to 
establish the final model reported. Steroid use and diagnosis category were included in all 
multivariable models as these were the central predictors evaluated. Diagnosis and coma 
grade were evaluated as categorical predictors, and pH was analyzed as a dichotomous 
variable around its median (7.4). In addition, the components of MELD (bilirubin, INR and 
creatinine) were analyzed but not included in multivariable models along with the MELD 
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score due to collinearity. Statistical analysis was performed using STATA 10.0 (College 
Station, TX, USA) and SPSS 18 (IBM, USA). A p value of <0.05 was considered 
statistically significant.
Results
Characteristics of Study Population
A total of 361 patients were studied, 18, 45, and 36% of whom were initially diagnosed with 
AI-ALF, indeterminate ALF, and DI-ALF, respectively. Clinical characteristics of the 3 
groups of patients are depicted in Table 1. Although baseline characteristics were generally 
similar between groups, patients with AI-ALF tended to be older (p=0.001) and more likely 
to be female (p=0.001) than those with DI-ALF or indeterminate ALF.
Overall, 62 patients (17%) received some form of corticosteroid therapy (Table 1). Patients 
with an initial diagnosis of AI-ALF had the highest rate of corticosteroid use (38%), higher 
than those with indeterminate or DI-ALF (13% and 12%, respectively; p<0.001). There were 
also statistically significant differences in several laboratory values between groups, 
including AST, ALT, creatinine, and MELD score, all of which tended to be highest in the 
indeterminate group (Table 1). The minority of patients had anti-nuclear (ANA), anti-
mitochondrial (AMA) and anti-smooth muscle antibodies (ASMA) recorded. Among these, 
ANA was significantly more likely to be positive in patients with AIH-ALF. There were no 
significant differences in mean globulin levels between the groups.
Corticosteroid dose
Complete data on dose and duration of corticosteroids administered was only available in a 
proportion of patients (in 72% in AI-ALF, 50% of DI-ALF, and 62% of indeterminate 
cases). The majority of patients received prednisone (8 AI-ALF, 7 DI-ALF, and 12 
indeterminate ALF), The mean daily dose of prednisone in the 3 groups was similar (42.5 
mg for AI-ALF, 41.6 mg for indeterminate ALF, and 42.3 mg for DI-ALF). Only a few 
patients in each group received methylprednisolone (Solumedrol®) (5 AI-ALF, 2 DI-ALF 
and 1 indeterminate ALF). Methylprednisolone doses were therefore converted to the 
prednisone equivalents for analysis. Among those with known steroid doses, the mean 
cumulative steroid dose (in prednisone equivalents) was 1287 ± 1144 mg. The median daily 
dose (50 mg AI-ALF, 60 mg DI-ALF and 40 mg indeterminate-ALF) and median duration 
of steroid therapy (24 days AI-ALF, 32.5 days DI-ALF and 31 days indeterminate ALF) 
were similar between groups. The baseline characteristics of the patients who received 
steroids versus those that did not were generally similar, though the average age of those 
who received steroids was higher (Table 2). In addition, admission INR was lower in the 
patients who received steroids than in the patients that did not receive steroids (2.64 vs. 3.78, 
p=0.005).
Effects of corticosteroids on overall survival in ALF
Sixty-six percent (238 of 361 patients) survived, while 34% (123 patients) died, and 44% 
(159 patients) received a liver transplant. Overall survival among all patients who received 
corticosteroids was 61%, compared to 66% in those who did not receive corticosteroids 
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(p=0.41; Figure 1). Similarly, corticosteroid administration had no apparent effect on overall 
survival of patients with an initial diagnosis of AI-ALF (60% with steroids vs. 73% without 
steroids; p=0.27). Thirty-four patients had liver histology available for analysis of features of 
autoimmunity. After reclassification of these 34 patients according to histological criteria of 
AI-ALF,4 overall survival was similar in patients who received corticosteroids compared to 
those who did not (66% vs. 68%, respectively; p=0.53). In the subgroup of patients with DI-
ALF, survival was 69% for those who received corticosteroids versus 66% for those who did 
not (p= 0.82), and in patients with indeterminate ALF, survival was 57% for those who 
received steroids versus 66% who did not (p=0.44). Similar results were obtained when the 
data were analyzed after reclassification according to liver histopathology: overall survival 
in patients with indeterminate ALF was 79% in those who received corticosteroids 
compared to 66% who did not (p=0.20).
Effects of corticosteroids on spontaneous survival in ALF
SS among patients who received corticosteroids (35%) was significantly higher than in 
patients who did not receive corticosteroids (23%; p=0.047) (Figure 1). However, there were 
no significantly differences in SS between steroid groups in any particular diagnosis 
subgroup, including those with AI-ALF (32% v. 20%, respectively, p=0.25). In addition, 
reassignment of etiology based upon a histological diagnosis of AI-ALF also yielded no 
difference (26% in those who received corticosteroids and 21% in those who did not 
(p=0.41).
Analysis of outcome according to severity of ALF
We hypothesized that the benefit of corticosteroids might be limited to patients with 
relatively less severe ALF, and subsequently analyzed the effect of steroid administration on 
overall and spontaneous survival according quartiles of AST, ALT and MELD. There were 
no statistically significant differences in SS in patients who received corticosteroids among 
all quartiles of ALT (Figure 2) or AST (data not shown). The highest 50% of ALT values 
had improved spontaneous survival compared to those not receiving steroid therapy (54% vs 
25%, respectively, p=0.003), and numerically higher overall survival (75% vs 61%, 
respectively, p=0.20). (Figure 2)
Steroid administration did not result in any difference in overall survival or SS in patients 
with MELD scores in the lowest three quartiles (Figure 3). In contrast, there was 
significantly lower overall survival in patients who received steroids in the highest MELD 
quartile (MELD > 40, 43%% v. 70%, respectively, p=0.03, Figure 3).
Subgroup analysis based upon encephalopathy stages 1-4 was also performed, and no 
differences in outcome were observed in patients who received or did not receive 
corticosteroids (data not shown).
Logistic Regression to Predict Mortality and Spontaneous Survival
Logistic regression was performed to identify independent predictors of overall mortality 
and SS. Steroid use and diagnosis category were not predictive of overall mortality in uni- or 
multivariable models (Table 3). In the final model to predict overall mortality, age (OR 1.37 
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per 10 years), coma grade (OR 2.02 for stage 2, 2.65 for stage 3 and 5.29 for stage 4), 
MELD (OR 1.07 per MELD point) and pH <7.4 (OR 3.09) were significantly predictive, 
controlling for steroid treatment and diagnosis category. In addition, steroid use was 
associated with diminished spontaneous survival (OR 1.80, p=0.049) in univariate analysis. 
However, in the final model for SS, male gender (OR 1.58), the need for ventilator support 
(OR 0.21), MELD (0.93) and ALT (1.02 per 100 U/L) were significantly predictive, while 
steroid use (OR 1.8, p=0.12) and diagnosis category were not significant (Table 4). Though 
the individual components of MELD were predictive of survival in some univariate and 
multivariable analyses they did not perform as well as MELD and thus were not included in 
the final multivariable models (Tables 3 and 4).
Effects of corticosteroids on the incidence of infection
Infection is a frequent complication of ALF, and the risk of increasing the incidence of 
infection has been cited as a rationale to avoid corticosteroids in this patient population. The 
overall rate of infection in patients was high but similar in those who received 
corticosteroids (42%) and those who did not (40%; p=0.733). The rate of infection also did 
not differ in subgroups according to etiology (Data not shown).
Discussion
In this prospectively collected, non-randomized study of large numbers of patients with ALF 
we demonstrated that corticosteroids did not improve overall survival in AI-ALF, DI ALF, or 
indeterminate ALF. In multivariable models, known predictors of poor outcomes in liver 
failure including age, coma grade, MELD and pH<7.4 were the only significant predictors of 
mortality, controlling for steroid use and diagnosis category. Interestingly, corticosteroid use 
was significantly associated with lower overall survival in high MELD patients. Although 
steroid use was marginally associated improved SS in univariate analysis, this difference did 
not persist in multivariable analysis after controlling for important clinical predictors of 
outcomes. In multivariable analysis controlling for steroid use and diagnosis category, the 
need for mechanical ventilation and MELD were significantly associated with diminished 
rates of SS, while ALT was significantly associated with increased SS. One potential 
explanation for the lack of benefit of corticosteroids overall may be selection bias. Patients 
in our study who received corticosteroids might have been more ill than those who did not, 
which may have biased the results towards making corticosteroids appear less effective. 
However, this is unlikely as the average MELD score in patients who received 
corticosteroids was similar to those who did not, and INR was actually higher in the no 
steroid group.
Kings College criteria were not assessed as all required components were not available for 
all patients. However it has previously been shown that MELD score has an excellent utility 
in the prediction of outcomes in ALF, and correlates equally with Kings College Criteria17. 
Subgroup analyses based on either MELD or degree of encephalopathy showed equivalent 
results, suggesting that selection bias based upon disease severity was not the primary factor 
responsible for our results.
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Based upon observations in patients with non-ALF autoimmune hepatitis 9, patients with AI-
ALF would reasonably be expected to respond to corticosteroids. However, we did not 
identify survival benefit in patients with AI-ALF who received corticosteroids, and noted a 
non-significant trend towards decreased survival in this group. Although this observation 
remained unchanged even after reclassification of etiology based on histology, it remains 
possible that some patients were misclassified. Unfortunately, given the retrospective nature 
of this study and lack of biopsy data in all patients, the “Revised Original Scoring System of 
the International Autoimmune Hepatitis Group” was unable to be calculated. However, as 
biopsy is not always possible in the acute setting in clinical practice, the diagnostic approach 
utilized does reflect the “real world” experience at experienced liver centers in the US. 
Overall, 38% of the total AI-ALF group were ANA negative. However, when the data for 
this cohort was reviewed for the study by an independent pathologist and only those with a 
histopathologically confirmed diagnosis of AIH were analyzed, steroids still showed no 
benefit. This sensitivity analysis supports our conclusion.
Another possible explanation for the lack of benefit of steroid treatment for AI-ALF patients 
in this cohort is that AI-ALF may have a different pathogenesis than classical autoimmune 
hepatitis, or that the condition of patients with AI-ALF is too advanced to allow for rescue 
with corticosteroids. Indeed, patients with acute presentations of autoimmune hepatitis have 
been shown to be less steroid responsive than patients with more chronic presentations, and 
have significant biochemical and histologic differences.4,18,19 Specifically, patients with 
acute presentations of AI-ALF more frequently have centrilobular necro-inflammatory 
changes than those with classical AIH, a histological feature of severe, and treatment-
refractory AIH and acute cellular rejection in transplant recipients.4,20 Based on the present 
study, patients with AI-ALF often have irreversible liver damage with or without treatment 
with corticosteroids, and most will die without liver transplantation. Larger cohorts will be 
required to determine whether these trends are clinically significant.
Despite the observation that administering corticosteroids was not associated with an overall 
survival benefit, and potentially increased mortality in high MELD patients, there were no 
statistically significant differences in the rate of infections in the patients that received 
corticosteroids compared to the patients who did not. Previous studies have raised concern 
that corticosteroids increased infectious complications in patients with ALF 8. Thus, the 
explanation for the decreased survival in patients treated with corticosteroids is unclear.
In our subgroup analysis of patients categorized by disease severity, only patients who 
received corticosteroids and had ALT in the higher 50% of values had improved spontaneous 
survival (54% steroid users vs 25% patients who did not receive steroids (p=0.003) and 
modestly improved overall survival (75%), compared to those not receiving steroid therapy 
(61%, p=0.2 Figure 2). We postulate that higher ALT may be a surrogate for an 
inflammatory process that is more corticosteroid-sensitive than other mechanisms of injury.
Overall, our data suggest that patients with a higher ALT and lower MELD scores may 
benefit from a liver biopsy since this group may be more likely to respond favorably to 
steroid administration. In contrast, patients with lower ALT and higher MELD scores are 
less likely to respond and will usually require OLT. In these cases liver biopsy does not seem 
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warranted as intervention with steroids will not improve survival and may even be 
detrimental. Our findings are similar to previous studies that have demonstrated that patients 
with higher ALT values have an increased capacity to regenerate and, consequently, better 
survival rates.21 In fact, cirrhotic livers have lower elevated liver enzymes, particularly in 
cases of acute-on-chronic liver failure.22
Finally, it has recently been shown that steroids in higher doses (prednisone 2-20 mg/kg/day 
over 3-7days) in combination with UDCA might be useful in drug induced liver injury23,24. 
In that study, patients that received steroids had a decrease in bilirubin and transaminases to 
less than 50% of peak values in 2 weeks and normalized in 4-8 weeks. The greatest benefit 
was in patients who had immune–mediated DILI. The number of patients in our study with 
DI-ALF who received both steroids and ursodiol is too small to perform any meaningful 
analyses. However, it is possible that the steroid dose and/or duration in this study was not 
sufficiently large or standardized to see maximal effects, or that steroids could be of greater 
benefit if used in combination with ursodiol or other agents, and additional studies are 
warranted in the future.
One major limitation of our study was that analyses were conducted retrospectively and the 
use of steroids was neither randomized nor standardized. Consequently, the administration 
of corticosteroids was not uniform in either in formulation, dose, route of administration, 
and duration of treatment. The use and duration of steroids was completely at the discretion 
of the provider and this alone could bias or confound our results. However, our findings 
across almost all subgroups suggest there is no survival benefit with steroid use, even in the 
AI-ALF group, in whom immunosuppression protocols with corticosteroids may be more 
likely to be standardized.
In conclusion, this prospectively collected large multicenter cohort study demonstrates no 
survival benefit with the administration of corticosteroids for patients with ALF of presumed 
autoimmune or drug induced etiology. Further investigation, if possible, should include a 
prospective, randomized study of the safety and efficacy of corticosteroids in patients with 
AI- and DI-ALF. In the interim, based upon the data presented, the risks and benefits of 
corticosteroid administration should be carefully weighed and early discontinuation 
considered in the absence of a clear salutary effect, especially in high MELD patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Overall and Spontaneous Survival among different etiologies of ALF
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Figure 2. 
Overall and Spontaneous Survival among Quartiles of ALT
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Figure 3. 
Overall and Spontaneous Survival among Quartiles of MELD
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Table 1
Baseline demographics by diagnosis group.
Variable AI-ALF N=66 DI-ALF N=131 Indeterminate N=164 P-value
Gender (%)
  Male 11 (17) 40 (31) 70 (43) 0.001
  Female 55 (83) 91 (69) 94 (57)
Age, Mean (SD) 46 (16) 44 (14) 39 (15) 0.001
Race (%)
  White 37 (56) 91 (69) 118 (72)
0.20
  African American 18 (27) 21 (16) 25 (15)
  Asian 5 (8) 10 (8) 10 (6)
  Native American 0 (0) 5 (4) 4 (2)
  Other 6 (9) 5 (4) 7 (4)
Ethnicity (%)
  Non-Hispanic 52 (79) 112 (86) 146 (89) 0.13
  Hispanic 14 (21) 18 (14) 18 (11)
Mean MELD (SD) 30.9 (9.5) 32.8 (8.8) 34.5 (9.5) 0.03
Laboratory values, mean (SD)
  AST (U/L) 619 (560) 1190 (1997) 2193 (3640) <0.001
  ALT (U/L) 601 (510) 1227 (1799) 1696 (2235) <0.001
  Total Bilirubin (mg/dL) 23.2 (9.1) 20.9 (11.4) 21.0 (12.7) 0.37
  Creatinine (mg/dL) 1.5 (1.4) 2.0 (1.8) 2.2 (1.8) 0.02
  INR 3.33 (3.17) 3.44 (2.37) 3.76 (3.12) 0.48
Positive autoimmune serologies (%)*
  ASMA 15/24 (63) 8/20 (40) 11/30 (37) 0.14
  ANA 39/41 (95) 25/34 (74) 32/39 (82) 0.03
  AMA 1/7 (14) 1/12 (8) 1/13 (8) 0.88
Globulin, mean (SD) 3.85 (1.72) 2.99 (1.41) 3.38 (6.8) .56
Coma grade (%)
 1 20 (30) 42 (32) 36 (22)
 2 24 (36) 41 (31) 46 (28) 0.12
 3 13 (20) 26 (20) 38 (49)
 4 9 (14) 22 (17) 44 (27)
Ventilatory Support (%) 28 (42) 63 (39) 103 (63) 0.005
Steroid Use (%) 25 (38) 16 (12) 21 (13)
  Total number of subjects 25 16 21 <0.001
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Variable AI-ALF N=66 DI-ALF N=131 Indeterminate N=164 P-value
  Daily Prednisone Dose**, Median (IQR) 50 (30-61.3) 60 (40-62) 40 (23-50)
  Days of Prednisone, Median (IQR) 24 (6.3-57.5) 32.5 (24.3-36.3) 31 (17.3-73)
*Autoimmune serologies were evaluated in the minority of patients (as indicated) and were considered positive with a titer of ≥ 1:40.
**Complete data on prednisone or prednisone equivalent dose was available in 12/25 AI-ALF cases, 7/16 DI-ALF cases and 8/21 indeterminate 
cases.
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Table 2
Baseline characteristics by steroid use.
Variable Steroid (n=62) No steroid (n=299) P-value
Gender (%)
  Male 22 (35) 99 (33) 0.72
  Female 40 (65) 200 (67)
Age, mean (SD) 46 (15) 41 (15) 0.02
Race-N(%)
  White 45 (73) 201 (67) 0.68
  African American 10 (16) 54 (18)
  Asian 2 (3) 23 (8)
  Native American 1 (2) 3 (1)
  Other 4 (6) 18 (6)
Ethnicity (%)
  Non-Hispanic 55 (89) 255 (86) 0.52
  Hispanic 7 (11) 43 (14)
MELD, mean (SD) 31.9 (9.9) 33.5 (9.2) 0.24
Laboratory values, mean (SD)
  AST (U/L) 1007 (2459) 1653 (2871) 0.10
  ALT (U/L) 897 (1375) 1414 (1990) 0.06
  Total Bilirubin (mg/dL) 22.4 (12.6) 21.2 (11.5) 0.44
  Creatinine (mg/dL) 2.1 (1.8) 2.0 (1.7) 0.53
  INR 2.64 (1.3) 3.76 (3.08) 0.005
  pH 7.43 (0.07) 7.37 (0.62) 0.51
Autoimmune serologies, positive (%)*
  ASMA 11/21 (52) 23/53 (43) 0.48
  ANA 18/20 (90) 78/94 (8.3) 0.43
  AMA 2/7 (29) 1/25 (4) 0.05
Coma grade (%)
 1 22 (35) 76 (25) 0.41
 2 18 (29) 93 (31)
 3 12 (19) 65 (22)
 4 10 (16) 65 (22)
Ventilatory Support (%) 28 (45) 166 (56) 0.14
*Autoimmune serologies were evaluated in the minority of patients (as indicated) and were considered positive with a titer of ≥ 1:40.
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Table 3
Uni- and multivariable analysis to predict overall mortality.
Univariate Multivariate
Variable OR p-value OR p-value
Steroid treatment 1.27 0.72 1.56 0.19
Diagnosis
 AI-ALF -- -- -- --
 DI-ALF 1.10 0.78 1.22 0.59
 Indeterminate 1.17 0.51 1.00 1.00
Age (per 10 years) 1.37 <0.001 1.39 <0.001
Coma grade
 1 -- -- -- --
 2 2.02 0.03 1.74 0.12
 3 2.65 0.006 2.37 0.02
 4 5.29 <0.001 5.18 <0.001
Ventilatory Support 3.11 <0.001 -- --
MELD 1.07 <0.001 1.05 0.001
Creatinine (mg/dL) 1.29 <0.001 -- --
pH<7.4 3.09 <0.001 2.68 0.002
*Additional variables tested and not significant with a p<0.2 include: gender, AST, ALT, bilirubin, INR.
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Table 4
Uni- and multivariable analysis to predict spontaneous survival.
Univariate Multivariate
Variable OR p-value OR p-value
Steroid treatment 1.80 0.049 1.80 0.12
Diagnosis
 AI-ALF -- -- -- --
 DI-ALF 1.18 0.63 1.49 0.33
 Indeterminate 1.00 0.98 1.36 0.46
Male gender 1.58 0.07 -- --
Coma grade
 1 -- -- -- --
 2 0.56 0.05
 3 0.50 0.04
 4 0.22 <0.001
Ventilatory Support 0.24 <0.001 0.21 <0.001
MELD 0.93 <0.001 0.93 <0.001
INR 0.84 0.01 -- --
ALT (per 100 U/L) 1.02 <0.001 1.04 <0.001
AST (per 100 U/L) 1.01 0.004 -- --
Bilirubin 0.93 <0.001 -- --
pH<7.4 0.60 0.13 -- --
*Additional variables tested and not significant with a p<0.2 include: age, creatinine.
Hepatology. Author manuscript; available in PMC 2016 May 26.
